134 related articles for article (PubMed ID: 25735339)
1. Ginsenoside Rh2 differentially mediates microRNA expression to prevent chemoresistance of breast cancer.
Wen X; Zhang HD; Zhao L; Yao YF; Zhao JH; Tang JH
Asian Pac J Cancer Prev; 2015; 16(3):1105-9. PubMed ID: 25735339
[TBL] [Abstract][Full Text] [Related]
2. Ginsenoside Rh2 mediates changes in the microRNA expression profile of human non-small cell lung cancer A549 cells.
An IS; An S; Kwon KJ; Kim YJ; Bae S
Oncol Rep; 2013 Feb; 29(2):523-8. PubMed ID: 23152132
[TBL] [Abstract][Full Text] [Related]
3. The reversal effect of Ginsenoside Rh2 on drug resistance in human colorectal carcinoma cells and its mechanism.
Liu GW; Liu YH; Jiang GS; Ren WD
Hum Cell; 2018 Jul; 31(3):189-198. PubMed ID: 29582366
[TBL] [Abstract][Full Text] [Related]
4. Induction of apoptosis and reversal of permeability glycoprotein-mediated multidrug resistance of MCF-7/ADM by ginsenoside Rh2.
Zhang H; Gong J; Zhang H; Kong D
Int J Clin Exp Pathol; 2015; 8(5):4444-56. PubMed ID: 26191135
[TBL] [Abstract][Full Text] [Related]
5. Ginsenoside Rh2 induces cell cycle arrest and differentiation in human leukemia cells by upregulating TGF-β expression.
Chung KS; Cho SH; Shin JS; Kim DH; Choi JH; Choi SY; Rhee YK; Hong HD; Lee KT
Carcinogenesis; 2013 Feb; 34(2):331-40. PubMed ID: 23125221
[TBL] [Abstract][Full Text] [Related]
6. β-Elemene Reverses Chemoresistance of Breast Cancer Cells by Reducing Resistance Transmission via Exosomes.
Zhang J; Zhang HD; Yao YF; Zhong SL; Zhao JH; Tang JH
Cell Physiol Biochem; 2015; 36(6):2274-86. PubMed ID: 26279432
[TBL] [Abstract][Full Text] [Related]
7. Methylation-regulated miR-149 modulates chemoresistance by targeting GlcNAc N-deacetylase/N-sulfotransferase-1 in human breast cancer.
He DX; Gu XT; Li YR; Jiang L; Jin J; Ma X
FEBS J; 2014 Oct; 281(20):4718-30. PubMed ID: 25156775
[TBL] [Abstract][Full Text] [Related]
8. A pathway-based approach for identifying biomarkers of tumor progression to trastuzumab-resistant breast cancer.
Nam S; Chang HR; Jung HR; Gim Y; Kim NY; Grailhe R; Seo HR; Park HS; Balch C; Lee J; Park I; Jung SY; Jeong KC; Powis G; Liang H; Lee ES; Ro J; Kim YH
Cancer Lett; 2015 Jan; 356(2 Pt B):880-90. PubMed ID: 25449779
[TBL] [Abstract][Full Text] [Related]
9. Ginsenoside Rh2 inhibits proliferation and migration of medulloblastoma Daoy by down-regulation of microRNA-31.
Chen Y; Shang H; Zhang S; Zhang X
J Cell Biochem; 2018 Aug; 119(8):6527-6534. PubMed ID: 29377269
[TBL] [Abstract][Full Text] [Related]
10. TGF-β1-induced miR-202 mediates drug resistance by inhibiting apoptosis in human osteosarcoma.
Lin Z; Song D; Wei H; Yang X; Liu T; Yan W; Xiao J
J Cancer Res Clin Oncol; 2016 Jan; 142(1):239-46. PubMed ID: 26276504
[TBL] [Abstract][Full Text] [Related]
11. Bioinformatic identification of chemoresistance-associated microRNAs in breast cancer based on microarray data.
Wang YW; Zhang W; Ma R
Oncol Rep; 2018 Mar; 39(3):1003-1010. PubMed ID: 29328395
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase 4 mediates SMAD family member 4 deacetylation and induces 5-fluorouracil resistance in breast cancer cells.
Yu SL; Lee DC; Son JW; Park CG; Lee HY; Kang J
Oncol Rep; 2013 Sep; 30(3):1293-300. PubMed ID: 23817620
[TBL] [Abstract][Full Text] [Related]
13. miR-222 induces Adriamycin resistance in breast cancer through PTEN/Akt/p27
Wang DD; Yang SJ; Chen X; Shen HY; Luo LJ; Zhang XH; Zhong SL; Zhao JH; Tang JH
Tumour Biol; 2016 Nov; 37(11):15315-15324. PubMed ID: 27699665
[TBL] [Abstract][Full Text] [Related]
14. Identification and characterization of microRNAs expressed in human breast cancer chemo-resistant MCF-7/Adr cells by Solexa deep-sequencing technology.
Xu P; Wang L; Huang L; Li W; Lv S; Lv M; Ma J; Zhou Q; Wu X; Fu Z; Lu C; Yin H
Biomed Pharmacother; 2015 Oct; 75():173-8. PubMed ID: 26293775
[TBL] [Abstract][Full Text] [Related]
15. Transcriptional targeting of human liver carboxylesterase (hCE1m6) and simultaneous expression of anti-BCRP shRNA enhances sensitivity of breast cancer cells to CPT-11.
Mishra MN; Vangara KK; Palakurthi S
Anticancer Res; 2014 Nov; 34(11):6345-51. PubMed ID: 25368234
[TBL] [Abstract][Full Text] [Related]
16. Enforced expression of hsa-miR-125a-3p in breast cancer cells potentiates docetaxel sensitivity via modulation of BRCA1 signaling.
Xu X; Lv YG; Yan CY; Yi J; Ling R
Biochem Biophys Res Commun; 2016 Oct; 479(4):893-900. PubMed ID: 27693788
[TBL] [Abstract][Full Text] [Related]
17. Ginsenoside Rh2 Suppresses Breast Cancer Cell Proliferation by Epigenetically Regulating the Long Noncoding RNA C3orf67-AS1.
Jeong D; Ham J; Park S; Kim HW; Kim H; Ji HW; Kim SJ
Am J Chin Med; 2019; 47(7):1643-1658. PubMed ID: 31645124
[TBL] [Abstract][Full Text] [Related]
18. Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin.
Pogribny IP; Filkowski JN; Tryndyak VP; Golubov A; Shpyleva SI; Kovalchuk O
Int J Cancer; 2010 Oct; 127(8):1785-94. PubMed ID: 20099276
[TBL] [Abstract][Full Text] [Related]
19. The microRNA miR-181c enhances chemosensitivity and reduces chemoresistance in breast cancer cells via down-regulating osteopontin.
Han B; Huang J; Han Y; Hao J; Wu X; Song H; Chen X; Shen Q; Dong X; Pang H; Cai L
Int J Biol Macromol; 2019 Mar; 125():544-556. PubMed ID: 30537505
[TBL] [Abstract][Full Text] [Related]
20. Ginsenoside Rh2 Targets EGFR by Up-Regulation of miR-491 to Enhance Anti-tumor Activity in Hepatitis B Virus-Related Hepatocellular Carcinoma.
Chen W; Qiu Y
Cell Biochem Biophys; 2015 Jun; 72(2):325-31. PubMed ID: 25561284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
